NEW YORK — Petros Grivas, MD, PhD, medical oncologist and clinical director of the genitourinary cancers program at University of Washington and Fred Hutchinson Cancer Research Center, presented two talks at HemOnc Today New York.
One focused on whether immunotherapy or targeted therapy is the preferred option for newly diagnosed metastatic renal cell carcinoma.
The second addressed whether immunotherapy is the new standard for bladder cancer.
“It’s really exciting to see the emerging data across tumor types — particularly in the field of urothelial cancer, where we have a lot of genomic data and biomarker data that hopefully will find their way into clinical practice,” Grivas told HemOnc Today. “We’re not there yet, but we’re really making an effort huge effort to identify and dissect molecular biomarkers and disease biology.”
Disclosure: Grivas reports relationships with AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Driver Inc., EMD Serono, Heron Therapeutics, Janssen, Merck, Pfizer and QED Therapeutics.